Standard treatments such as everolimus (inhibitor of mammalian target of rapamycin [mTOR]) and sunitinib (inhibitor of receptor tyrosine kinases, including VEGFR) [36,37,38] were supported by patient tumor profiling [39,40] and drug studies in RT2 mice demonstrating their effectiveness [19,24]. This evidence concerns the gene NTRK1 and neoplasm.